Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

80.0%

4 terminated/withdrawn out of 5 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(100.0%)
3Total
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05222178Phase 1Terminated

Safety and Efficacy of HMI-103 in Participants With Classical PKU Due to PAH Deficiency

Role: lead

NCT03952156Phase 1Terminated

Gene Therapy Clinical Study in Adult PKU

Role: lead

NCT05238324Phase 1Withdrawn

Safety and Efficacy of HMI-203 in ERT-Treated Adults With MPS II

Role: lead

NCT04768348Terminated

Natural History Clinical Study in Adult PKU

Role: lead

NCT04348708Enrolling By Invitation

Long-Term Follow Up Study of Subjects Previously Administered HMI 102

Role: lead

All 5 trials loaded